Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALT NASDAQ:CSBR NASDAQ:FDMT NASDAQ:LRMR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$3.78-2.3%$3.75$2.90▼$11.16$341.56M0.182.44 million shs4.43 million shsCSBRChampions Oncology$6.57-32.1%$10.15$3.60▼$11.99$92.31M0.5139,077 shs32,633 shsFDMT4D Molecular Therapeutics$6.60-7.0%$5.95$2.23▼$13.59$331.59M2.86516,653 shs1.19 million shsLRMRLarimar Therapeutics$4.20-1.9%$3.74$1.61▼$9.50$354.29M0.911.22 million shs2.38 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune+8.40%+4.88%+6.91%-45.09%-47.91%CSBRChampions Oncology+2.74%+0.32%-13.95%-20.48%+54.21%FDMT4D Molecular Therapeutics+6.61%+0.42%+8.07%+71.91%-57.79%LRMRLarimar Therapeutics+4.90%+2.64%+17.26%+65.25%-37.52%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$3.78-2.3%$3.75$2.90▼$11.16$341.56M0.182.44 million shs4.43 million shsCSBRChampions Oncology$6.57-32.1%$10.15$3.60▼$11.99$92.31M0.5139,077 shs32,633 shsFDMT4D Molecular Therapeutics$6.60-7.0%$5.95$2.23▼$13.59$331.59M2.86516,653 shs1.19 million shsLRMRLarimar Therapeutics$4.20-1.9%$3.74$1.61▼$9.50$354.29M0.911.22 million shs2.38 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune+8.40%+4.88%+6.91%-45.09%-47.91%CSBRChampions Oncology+2.74%+0.32%-13.95%-20.48%+54.21%FDMT4D Molecular Therapeutics+6.61%+0.42%+8.07%+71.91%-57.79%LRMRLarimar Therapeutics+4.90%+2.64%+17.26%+65.25%-37.52%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALTAltimmune 2.57Moderate Buy$17.40360.32% UpsideCSBRChampions Oncology 3.00Buy$12.0082.65% UpsideFDMT4D Molecular Therapeutics 2.64Moderate Buy$30.40360.61% UpsideLRMRLarimar Therapeutics 3.00Buy$18.43338.78% UpsideCurrent Analyst Ratings BreakdownLatest CSBR, LRMR, ALT, and FDMT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/13/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated Rating8/30/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated Rating8/15/2025LRMRLarimar TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$22.00 ➝ $18.008/14/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated Rating8/13/2025ALTAltimmuneHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.008/13/2025ALTAltimmuneUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$26.00 ➝ $24.008/13/2025ALTAltimmuneB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$20.00 ➝ $18.008/12/2025FDMT4D Molecular TherapeuticsRoth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$44.00 ➝ $38.008/12/2025FDMT4D Molecular TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.008/1/2025FDMT4D Molecular TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.007/29/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated Rating(Data available from 9/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALTAltimmune$20K16,681.14N/AN/A$1.74 per share2.17CSBRChampions Oncology$56.94M1.59$0.45 per share14.61$0.26 per share25.27FDMT4D Molecular Therapeutics$40K7,705.50N/AN/A$11.05 per share0.60LRMRLarimar TherapeuticsN/AN/AN/AN/A$2.69 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALTAltimmune-$95.06M-$1.18N/AN/AN/A-438,730.03%-62.63%-55.29%11/11/2025 (Estimated)CSBRChampions Oncology$4.70M-$0.0633.50∞N/A5.19%87.76%9.95%N/AFDMT4D Molecular Therapeutics-$160.87M-$3.53N/AN/AN/A-594,375.81%-40.15%-36.43%11/12/2025 (Estimated)LRMRLarimar Therapeutics-$80.60M-$1.56N/AN/AN/AN/A-62.92%-53.98%10/29/2025 (Estimated)Latest CSBR, LRMR, ALT, and FDMT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/15/2025Q1 2026CSBRChampions OncologyN/A-$0.03N/A-$0.03N/A$13.99 million8/14/2025Q2 2025LRMRLarimar Therapeutics-$0.47-$0.41+$0.06-$0.41N/AN/A8/12/2025Q2 2025ALTAltimmune-$0.32-$0.27+$0.05-$0.27$0.00 million$0.01 million8/11/2025Q2 2025FDMT4D Molecular Therapeutics-$0.88-$0.98-$0.10-$0.98$0.52 million$0.01 million7/23/2025Q4 2025CSBRChampions OncologyN/A-$0.13N/A-$0.13N/A$12.35 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALTAltimmuneN/AN/AN/AN/AN/ACSBRChampions OncologyN/AN/AN/AN/AN/AFDMT4D Molecular TherapeuticsN/AN/AN/AN/AN/ALRMRLarimar TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALTAltimmune0.0920.4420.44CSBRChampions OncologyN/A0.930.94FDMT4D Molecular TherapeuticsN/A8.758.75LRMRLarimar TherapeuticsN/A5.465.46Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALTAltimmune78.05%CSBRChampions Oncology41.30%FDMT4D Molecular Therapeutics99.27%LRMRLarimar Therapeutics91.92%Insider OwnershipCompanyInsider OwnershipALTAltimmune4.40%CSBRChampions Oncology46.98%FDMT4D Molecular Therapeutics9.60%LRMRLarimar Therapeutics4.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALTAltimmune5088.26 million84.37 millionOptionableCSBRChampions Oncology14313.78 million7.31 millionOptionableFDMT4D Molecular Therapeutics12046.70 million42.22 millionOptionableLRMRLarimar Therapeutics3082.78 million79.05 millionOptionableCSBR, LRMR, ALT, and FDMT HeadlinesRecent News About These CompaniesGoldman Sachs Group Inc. Lowers Stock Position in Larimar Therapeutics, Inc. $LRMRSeptember 17 at 3:45 AM | marketbeat.comLarimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Consensus Recommendation of "Buy" from BrokeragesSeptember 15, 2025 | marketbeat.comLarimar Therapeutics, Inc. (NASDAQ:LRMR) Given Consensus Recommendation of "Buy" by AnalystsSeptember 14, 2025 | americanbankingnews.comCubist Systematic Strategies LLC Has $762,000 Stock Holdings in Larimar Therapeutics, Inc. $LRMRSeptember 12, 2025 | marketbeat.comLeerink Partnrs Has Bearish Outlook for LRMR FY2025 EarningsSeptember 9, 2025 | marketbeat.comFY2025 Earnings Estimate for LRMR Issued By Leerink PartnrsSeptember 9, 2025 | americanbankingnews.comLarimar Therapeutics, Inc. $LRMR Shares Bought by Alyeska Investment Group L.P.September 8, 2025 | marketbeat.comNuveen LLC Invests $376,000 in Larimar Therapeutics, Inc. $LRMRSeptember 8, 2025 | marketbeat.comDriehaus Capital Management LLC Decreases Stock Holdings in Larimar Therapeutics, Inc. $LRMRSeptember 3, 2025 | marketbeat.comLarimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Consensus Recommendation of "Buy" from AnalystsAugust 21, 2025 | marketbeat.comQ4 Earnings Estimate for LRMR Issued By Leerink PartnrsAugust 20, 2025 | marketbeat.comQ3 EPS Forecast for Larimar Therapeutics Lifted by AnalystAugust 19, 2025 | marketbeat.comWilliam Blair Analysts Lift Earnings Estimates for LRMRAugust 19, 2025 | marketbeat.comLeerink Partners Keeps Their Buy Rating on Larimar Therapeutics (LRMR)August 16, 2025 | theglobeandmail.comLarimar Therapeutics (LRMR) Gets a Buy from Truist FinancialAugust 16, 2025 | theglobeandmail.comLarimar Therapeutics Advances Nomlabofusp Program Toward 2026 FDA FilingAugust 16, 2025 | msn.com3 Best Stocks to Buy Now, 8/15/2025, According to Top AnalystsAugust 15, 2025 | msn.comLarimar Therapeutics Announces $64.4 Million Stock OfferingAugust 15, 2025 | theglobeandmail.comLarimar Therapeutics price target lowered to $18 from $22 at Citizens JMPAugust 15, 2025 | msn.comLarimar Therapeutics Advances Nomlabofusp Program Amid Financial LossesAugust 14, 2025 | tipranks.comLarimar Beats Q2 Loss EstimatesAugust 14, 2025 | aol.comANew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 20252 Data Center REITs That Look Good in Any PortfolioBy Sam Quirke | September 8, 2025Chevron Stock Outlook: Dividend Growth Meets InflationBy Chris Markoch | August 28, 20253 Healthcare Pathbreakers With Long-Term TailwindsBy Nathan Reiff | September 1, 2025Dollar Tree Plunges Into Buy-Zone: A Robust Rebound Is ExpectedBy Thomas Hughes | September 4, 2025CSBR, LRMR, ALT, and FDMT Company DescriptionsAltimmune NASDAQ:ALT$3.78 -0.09 (-2.33%) Closing price 04:00 PM EasternExtended Trading$3.79 +0.01 (+0.29%) As of 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.Champions Oncology NASDAQ:CSBRChampions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.4D Molecular Therapeutics NASDAQ:FDMT$6.60 -0.50 (-7.04%) Closing price 04:00 PM EasternExtended Trading$6.75 +0.15 (+2.21%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.Larimar Therapeutics NASDAQ:LRMR$4.20 -0.08 (-1.87%) Closing price 04:00 PM EasternExtended Trading$4.28 +0.08 (+1.79%) As of 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas FedEx Delivers Good News: The Bottom Is in for This Stock Tesla: 2 Reasons to Love Musk's $1B Buy, 1 Reason to Be Bearish Azure Leads While AI Excitement Fuels Microsoft Stock The Fed Cut Rates: What Now for the S&P 500 and Equity Markets? Darden Restaurants: A Textbook Buy-the-Dip Opportunity McDonald’s: New All-Time Highs Are Inevitable Workday Rising… To Fresh Record High Stock Prices 3 Reasons Amazon Could Be at an All-Time High by October Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
